OKYO Pharma Announces U.S. IND Filing on OK-101 for the Treatment of Dry Eye DiseaseGlobeNewsWire • 11/21/22
OKYO Pharma Hosting Key Opinion Leader Event Introducing OK-101 as a Potential Treatment for Dry Eye DiseaseGlobeNewsWire • 11/10/22
OKYO Pharma Limited Interview to Air on Bloomberg U.S. on the RedChip Money Report®GlobeNewsWire • 09/08/22
OKYO Pharma Limited Interview to Air on Bloomberg U.S. on the RedChip Money Report(R)Accesswire • 09/08/22
OKYO Pharma Plans Q4 2022 IND Filing of OK-101 to treat Dry Eye Disease with Subsequent Phase 2 Initiation Alongside Peptide Manufacturing Partner, AmbioPharmBusiness Wire • 08/30/22